{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:44:26Z","timestamp":1767854666529,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis Pharma, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00059-024-05248-z","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T14:02:25Z","timestamp":1713967345000},"page":"385-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of sacubitril\/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study","Anwendung von Sacubitril\/Valsartan bei Patienten mit Herzinsuffizienz in der Prim\u00e4rversorgung in Deutschland: die nichtinterventionelle AURORA-HF-Studie"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-283X","authenticated-orcid":false,"given":"Uwe","family":"Zeymer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Groves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Hupfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"5248_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s00392-015-0841-4","volume":"104","author":"C Ohlmeier","year":"2015","unstructured":"Ohlmeier\u00a0C, Mikolajczyk\u00a0R, Frick\u00a0J, Pr\u00fctz\u00a0F, Haverkamp\u00a0W, Garbe\u00a0E (2015) Incidence, prevalence and 1\u2011year all-cause mortality of heart failure in Germany: a\u00a0study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 104:688\u2013696","journal-title":"Clin Res Cardiol"},{"key":"5248_CR2","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00392-017-1138-6","volume":"106","author":"S St\u00f6rk","year":"2017","unstructured":"St\u00f6rk\u00a0S, Handrock\u00a0R, Jacob\u00a0J, Walker\u00a0J, Calado\u00a0F, Lahoz\u00a0R et\u00a0al (2017) Treatment of chronic heart failure in Germany: a\u00a0retrospective database study. Clin Res Cardiol 106:923\u2013932","journal-title":"Clin Res Cardiol"},{"key":"5248_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00392-014-0678-2","volume":"103","author":"U Tebbe","year":"2014","unstructured":"Tebbe\u00a0U, Tsch\u00f6pe\u00a0C, Wirtz\u00a0JH, Lokies\u00a0J, Turgonyi\u00a0E, Bramlage\u00a0P et\u00a0al (2014) Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 103:665\u2013673","journal-title":"Clin Res Cardiol"},{"key":"5248_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD, Bueno\u00a0H, Cleland\u00a0JGF, Coats\u00a0AJS et\u00a0al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"5248_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray\u00a0JJV, Packer\u00a0M, Desai\u00a0AS, Gong\u00a0J, Lefkowitz\u00a0MP, Rizkala\u00a0AR et\u00a0al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"5248_CR6","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","volume":"36","author":"AS Desai","year":"2015","unstructured":"Desai\u00a0AS, McMurray\u00a0JJV, Packer\u00a0M, Swedberg\u00a0K, Rouleau\u00a0JL, Chen\u00a0F et\u00a0al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart\u00a0J 36:1990\u20131997","journal-title":"Eur Heart J"},{"issue":"18","key":"5248_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"2016","author":"O Vardeny","year":"2016","unstructured":"Vardeny\u00a0O, Claggett\u00a0B, Packer\u00a0M, Zile\u00a0MR, Rouleau\u00a0J, Swedberg\u00a0K et\u00a0al (2016) Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 2016(18):1228\u20131234","journal-title":"Eur J Heart Fail"},{"key":"5248_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ehf2.12251","volume":"5","author":"H Norberg","year":"2018","unstructured":"Norberg\u00a0H, Bergdahl\u00a0E, Lindmark\u00a0K (2018) Eligibility of sacubitril-valsartan in a\u00a0real-world heart failure population: a\u00a0community-based single-centre study. Esc Heart Fail 5:337\u2013343","journal-title":"Esc Heart Fail"},{"key":"5248_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10557-019-06873-1","volume":"33","author":"J Simpson","year":"2019","unstructured":"Simpson\u00a0J, Benson\u00a0L, Jhund\u00a0PS, Dahlstr\u00f6m\u00a0U, McMurray\u00a0JJV, Lund\u00a0LH (2019) \u201cReal world\u201d eligibility for sacubitril\/valsartan in unselected heart failure patients: Data from the Swedish Heart Failure Registry. Cardiovasc Drugs Ther 33:315\u2013322","journal-title":"Cardiovasc Drugs Ther"},{"key":"5248_CR10","series-title":"Cardiol","first-page":"1011","volume-title":"Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: A\u00a0systematic review","author":"AS Tahhan","year":"2018","unstructured":"Tahhan\u00a0AS, Vaduganathan\u00a0M, Greene\u00a0SJ, Fonarow\u00a0GC, Fiuzat\u00a0M, Jessup\u00a0M et\u00a0al (2018) Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: A\u00a0systematic review. Cardiol, vol 3. JAMA, pp\u00a01011\u20131019"},{"key":"5248_CR11","doi-asserted-by":"publisher","first-page":"110596","DOI":"10.1016\/j.biopha.2020.110596","volume":"130","author":"A Mazza","year":"2020","unstructured":"Mazza\u00a0A, Townsend\u00a0DM, Torin\u00a0G, Schiavon\u00a0L, Camerotto\u00a0A, Rigatelli\u00a0G et\u00a0al (2020) The role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Biomed Pharmacother 130:110596","journal-title":"Biomed Pharmacother"},{"key":"5248_CR12","unstructured":"Zeymer U, Groves R, Merkel T. (2019) Treatment of patients with heart failure with reduced ejection fraction (HFrEF) in Germany: differences between cardiologists and primary care physicans. Eur J Heart Fail;21:233(P997)."},{"key":"5248_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00392-014-0743-x","volume":"103","author":"W Von Scheidt","year":"2014","unstructured":"Von Scheidt\u00a0W, Zugck\u00a0C, Pauschinger\u00a0M, Hambrecht\u00a0R, Bruder\u00a0O, Hartmann\u00a0A et\u00a0al (2014) Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol 103:1006\u20131014","journal-title":"Clin Res Cardiol"},{"key":"5248_CR14","doi-asserted-by":"crossref","unstructured":"Greene SJ, Felker GM. (2019) The urgency of doing: Addressing gaps in use of evidence-based medical therapy for heart failure. JACC Hear Fail;7:22\u201324.","DOI":"10.1016\/j.jchf.2018.11.006"},{"key":"5248_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10741-019-09777-2","volume":"24","author":"WJ Kruik-Koll\u00f6ffel","year":"2019","unstructured":"Kruik-Koll\u00f6ffel\u00a0WJ, Linssen\u00a0GCM, Kruik\u00a0HJ, Movig\u00a0KLL, Heintjes\u00a0EM, van der Palen\u00a0J (2019) Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Heart Fail Rev 24:499\u2013510","journal-title":"Heart Fail Rev"},{"key":"5248_CR16","series-title":"Fail","first-page":"2318","volume-title":"Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril\/valsartan in primary care and cardiologist settings in","author":"R Wachter","year":"2020","unstructured":"Wachter\u00a0R, Klebs\u00a0S, Balas\u00a0B, Kap\u00a0E, Engelhard\u00a0J, Schlienger\u00a0R et\u00a0al (2020) Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril\/valsartan in primary care and cardiologist settings in. Fail, vol 7. ESC Heart, Germany, pp\u00a02318\u20132330"},{"key":"5248_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ejhf.1459","volume":"21","author":"M Komajda","year":"2019","unstructured":"Komajda\u00a0M, Sch\u00f6pe\u00a0J, Wagenpfeil\u00a0S, Tavazzi\u00a0L, B\u00f6hm\u00a0M, Ponikowski\u00a0P et\u00a0al (2019) Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21:921\u2013929","journal-title":"Eur J Heart Fail"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-024-05248-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05248-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:09:47Z","timestamp":1727298587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-024-05248-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5248"],"URL":"https:\/\/doi.org\/10.1007\/s00059-024-05248-z","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"17 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"U.\u00a0Zeymer declares the receipt of payment or honoraria for lectures, presentations, speakers bureaus: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi. R.\u00a0Groves is an employee of Novartis Pharma GmbH, the funder of the study. S.\u00a0Hupfer is an employee of Novartis Pharma GmbH, the funder of the study, and holds shares in Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}